Skip to main content
Tiziana Life Sciences Ltd logo

Tiziana Life Sciences Ltd — Investor Relations & Filings

Ticker · TLSA ISIN · BMG889121031 LEI · 984500769407C5E46F42 US Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2018-02-27 Annual Report
Country BM Bermuda
Listing US TLSA

About Tiziana Life Sciences Ltd

https://www.tizianalifesciences.com/

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's core strategy involves utilizing alternative drug delivery routes, such as intranasal administration, to modulate the immune system. Its lead clinical candidate, foralumab (TZLS-401), is the only fully human anti-CD3 monoclonal antibody being investigated for neurological conditions. Foralumab is in clinical development for the treatment of Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS), Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), and Multiple System Atrophy (MSA). The company's pipeline also includes an anti-IL-6 receptor monoclonal antibody (TZLS-501) for potential application in lung diseases.

Recent filings

Filing Released Lang Actions
Annual Report 2018
Annual Report Classification · 95% confidence The document is a confidential draft registration statement on Form 20-F/A (Amendment No. 1) submitted to the U.S. Securities and Exchange Commission. It includes detailed sections typical of a registration statement such as identity of directors, offer statistics, key information, financial information, and exhibits. The Form 20-F is a comprehensive annual report filed by foreign private issuers, similar to a 10-K for U.S. companies. The document contains substantive financial data and detailed company information, not merely an announcement or certification. Therefore, it is classified as an Annual Report equivalent filing.
2018-02-27 English
Annual Report 2018
Annual Report Classification · 100% confidence The document is a confidential draft registration statement submitted to the U.S. Securities and Exchange Commission (SEC) on Form 20-F. Form 20-F is an annual report filed by foreign private issuers, similar to the 10-K filed by U.S. companies. The document includes detailed sections such as Identity of Directors, Operating and Financial Review and Prospects, Financial Statements, and exhibits, which are typical components of a comprehensive annual report. The presence of financial statements prepared under IFRS and detailed disclosures further confirm this classification. Therefore, this document is an Annual Report equivalent filing under SEC regulations, specifically a Form 20-F annual report.
2018-02-27 English
Regulatory Filings 2018
Regulatory Filings
2018-02-22 English
Annual Report 2018
Annual Report Classification · 100% confidence The document is a confidential draft registration statement submitted to the U.S. Securities and Exchange Commission on Form 20-F. It includes detailed sections typical of a comprehensive annual report such as identity of directors, offer statistics, key information, financial information, operating and financial review, and financial statements. The presence of a fiscal year end reference and detailed table of contents with financial statements indicates this is a full annual report filing. The Form 20-F is the SEC's equivalent of the 10-K for foreign private issuers, which is an official yearly report covering company activity and full financial performance. Therefore, this document fits the definition of an Annual Report (10-K equivalent). The document length (15,000 characters) and content confirm it is the report itself, not just an announcement or certification.
2018-02-09 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from a company to the U.S. Securities and Exchange Commission (SEC) staff regarding comments on a confidential draft registration statement on Form 20-F. The letter addresses specific SEC comments on disclosures, scientific explanations, clinical trial data, intellectual property, accounting policies, and offering details. The presence of references to Form 20-F, detailed regulatory comments, and the company's responses indicate this is part of the registration process for a public offering or listing. This type of document is a regulatory filing responding to SEC comments on a registration statement, not the registration statement itself or a financial report. It is not an annual report, earnings release, or any other financial or governance report. It is a regulatory filing (RNS) as it is a formal communication with the SEC regarding compliance and disclosure issues related to a registration statement.
2018-02-08 English
Annual Report 2018
Annual Report Classification · 100% confidence The document is a confidential draft registration statement submitted to the U.S. Securities and Exchange Commission on Form 20-F. It includes detailed sections typical of a comprehensive annual report such as identity of directors, offer statistics, key information, financial statements, operating and financial review, and prospects. The presence of financial statements and extensive company information for the fiscal year indicates this is a full annual report filing. The Form 20-F is the SEC filing used by foreign private issuers to file their annual reports, equivalent to the 10-K for U.S. companies. Therefore, this document is classified as an Annual Report (10-K equivalent). The document length (15,000 characters) and content confirm it is the report itself, not just an announcement or certification.
2018-02-08 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.